跳转至内容
Merck

145726

Sigma-Aldrich

DL-酪氨酸

99%

别名:

(±)-2-氨基-3-(4-羟基苯基)丙酸, 3-(4-羟基苯基)-DL-丙氨酸

登录查看公司和协议定价


About This Item

线性分子式:
4-(HO)C6H4CH2CH(NH2)COOH
CAS号:
分子量:
181.19
Beilstein:
515881
EC號碼:
MDL號碼:
分類程式碼代碼:
12352209
PubChem物質ID:
NACRES:
NA.22

化驗

99%

形狀

powder

反應適用性

reaction type: solution phase peptide synthesis

mp

≥300 °C (lit.)

應用

peptide synthesis

SMILES 字串

NC(Cc1ccc(O)cc1)C(O)=O

InChI

1S/C9H11NO3/c10-8(9(12)13)5-6-1-3-7(11)4-2-6/h1-4,8,11H,5,10H2,(H,12,13)

InChI 密鑰

OUYCCCASQSFEME-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 1

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

dust mask type N95 (US), Eyeshields, Gloves


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Shannon L Maude et al.
Blood, 125(11), 1759-1767 (2015-02-04)
Early T-cell precursor (ETP) acute lymphoblastic leukemia (ALL) is a recently described subtype of T-ALL characterized by a unique immunophenotype and genomic profile, as well as a high rate of induction failure. Frequent mutations in cytokine receptor and Janus kinase
W D Phillips et al.
Experimental neurology, 270, 29-40 (2014-12-30)
Muscle-specific tyrosine kinase (MuSK) autoantibodies are the hallmark of a form of myasthenia gravis (MG) that can challenge the neurologist and the experimentalist. The clinical disease can be difficult to treat effectively. MuSK autoantibodies affect the neuromuscular junction in several
S P Gorantla et al.
Leukemia, 29(8), 1763-1770 (2015-03-13)
FIP1L1-PDGFRA is a constitutively activated kinase described in chronic eosinophilic leukemia (CEL) and hypereosinophilic syndrome (HES). Imatinib is clinically active in FIP1L1-PDGFRA-positive diseases. Using in vitro screening to identify imatinib-resistant mutations, we frequently detected a Phe to Ser exchange at
Philippe Menasché et al.
European heart journal, 36(12), 743-750 (2014-05-20)
There is now compelling evidence that cells committed to a cardiac lineage are most effective for improving the function of infarcted hearts. This has been confirmed by our pre-clinical studies entailing transplantation of human embryonic stem cell (hESC)-derived cardiac progenitors
Martin Schlumberger et al.
The New England journal of medicine, 372(7), 621-630 (2015-02-12)
Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor α, RET, and KIT, showed clinical activity in a phase 2 study involving patients with

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门